

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Sinco Pharmaceuticals Holdings Limited

兴科蓉医药控股有限公司

(Incorporated under the laws of the Cayman Islands with limited liability)

(Stock Code: 6833)

POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 13 MAY 2022

The Board is pleased to announce that all the resolutions proposed at the AGM held on 13 May 2022 were duly passed by way of poll.

Reference is made to the circular (“**Circular**”) and the notice (“**Notice**”) of annual general meeting (“**AGM**”) of Sinco Pharmaceuticals Holdings Limited (the “**Company**”) both dated 8 April 2022. Unless the context otherwise requires, capitalised terms used herein shall have the same meanings as those defined in the Circular.

As at the date of the AGM, the total number of issued Shares is 2,032,890,585 Shares, which is the total number of Shares entitling the holders to attend and vote for or against the resolutions proposed at the AGM. There was no restriction on any Shareholder casting votes on any of the proposed resolutions at the AGM. No Shareholder was required under the Listing Rules to abstain from voting on any of the resolutions at the AGM and no Shareholder was entitled to attend and abstain from voting in favour as set out under Rule 13.40 of the Listing Rules. No Shareholder has stated his/her/its intention in the Circular to vote against or to abstain from voting on any of the proposed resolutions at the AGM. All Directors attended the AGM.

The Company’s Hong Kong branch share registrar, Computershare Hong Kong Investor Services Limited, was appointed as the scrutineer at the AGM for the purpose of vote-taking.

The poll results in respect of all the resolutions proposed at the AGM are as follows:

ORDINARY RESOLUTIONS		No. of Votes (Approximate %)	
		For	Against
1.	To receive and adopt the audited consolidated financial statements of the Company for the year ended 31 December 2021 and the reports of the directors and independent auditor thereon.	135,020,000 100%	0 0%
2.	(a) To re-elect the following Directors:		
	(i) Mr. Huang Xiangbin as an executive Director;	135,020,000 100%	0 0%
	(ii) Mr. Wang Qing as an independent non-executive Director; and	135,020,000 100%	0 0%
	(b) To authorise the Board to fix the remuneration of the Directors.	135,020,000 100%	0 0%
3.	To re-appoint Ernst & Young as auditor of the Company to hold office until the conclusion of the next annual general meeting of the Company and to authorize the Board to fix their remuneration for the year ending 31 December 2022.	135,020,000 100%	0 0%
4.	(A) To grant a general mandate to the Directors to allot, issue and deal with additional Shares not exceeding 20% of the number of issued Shares.	130,080,000 96%	4,940,000 4%
	(B) To grant a general mandate to the Directors to repurchase Shares not exceeding 10% of the number of issued Shares.	135,020,000 100%	0 0%
	(C) Conditional upon the passing of ordinary resolutions numbered 4(A) and 4(B), to extend the authority granted to Directors pursuant to ordinary resolution numbered 4(A) to issue Shares by adding number of issued Shares which may be allotted by the Company pursuant to such general mandate of an amount representing the number of Shares repurchased under ordinary resolution numbered 4(B).	130,080,000 96%	4,940,000 4%

SPECIAL RESOLUTION		No. of Votes (Approximate%)	
		For	Against
5.	The proposed amendments to the Memorandum and Articles of Association be approved and adopted and the Directors be and are hereby authorised to do all such acts and things and execute all such documents and make all such arrangements as they shall, in their absolute discretion, deem necessary or expedient in connection with the implementation of or giving effect to the aforesaid adoption of the proposed amendments.	135,020,000 100%	0 0%

Note: Please refer to the Notice for the full text of the resolutions.

As more than 50% of votes were cast in favour of each of the ordinary resolutions numbered 1 to 4(C) and more than 75% of the votes were cast in favor of the special resolution numbered 5, all the above resolutions were duly passed at the AGM.

By order of the Board
Sinco Pharmaceuticals Holdings Limited
Huang Xiangbin
Chairman and Executive Director

Sichuan, the PRC, 13 May 2022

As at the date of this announcement, the executive Director is Mr. Huang Xiangbin; and the independent non-executive Directors are Mr. Lau Ying Kit, Mr. Wang Qing, Mr. Liu Wenfang and Mr. Bai Zhizhong.